Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler purchased 50,000 shares of the stock in a transaction dated Monday, August 21st. The stock was purchased at an average cost of $21.45 per share, for a total transaction of $1,072,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Accelerate Diagnostics, Inc. (NASDAQ AXDX) traded up 0.67% during trading on Wednesday, reaching $22.40. The company had a trading volume of 158,983 shares. The firm’s 50 day moving average price is $25.91 and its 200 day moving average price is $25.84. Accelerate Diagnostics, Inc. has a 12 month low of $19.20 and a 12 month high of $30.45. The firm’s market capitalization is $1.24 billion.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.40 million. Accelerate Diagnostics had a negative return on equity of 67.44% and a negative net margin of 5,062.48%. Equities analysts predict that Accelerate Diagnostics, Inc. will post ($1.20) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Accelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Purchases 50,000 Shares” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/accelerate-diagnostics-inc-axdx-director-jack-w-schuler-purchases-50000-shares/1518524.html.

A number of institutional investors have recently bought and sold shares of AXDX. Verition Fund Management LLC purchased a new position in Accelerate Diagnostics during the second quarter valued at $343,000. California State Teachers Retirement System boosted its position in Accelerate Diagnostics by 1.5% in the second quarter. California State Teachers Retirement System now owns 46,111 shares of the medical research company’s stock valued at $1,261,000 after buying an additional 700 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Accelerate Diagnostics by 13.0% in the second quarter. The Manufacturers Life Insurance Company now owns 21,125 shares of the medical research company’s stock valued at $578,000 after buying an additional 2,425 shares during the last quarter. State Street Corp boosted its position in Accelerate Diagnostics by 12.5% in the second quarter. State Street Corp now owns 475,078 shares of the medical research company’s stock valued at $12,993,000 after buying an additional 52,817 shares during the last quarter. Finally, Intrinsic Edge Capital Management LLC boosted its position in Accelerate Diagnostics by 181.1% in the second quarter. Intrinsic Edge Capital Management LLC now owns 62,082 shares of the medical research company’s stock valued at $1,698,000 after buying an additional 40,000 shares during the last quarter. Hedge funds and other institutional investors own 38.65% of the company’s stock.

A number of equities analysts recently commented on AXDX shares. BidaskClub downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. BTIG Research reiterated a “buy” rating and set a $34.00 price objective on shares of Accelerate Diagnostics in a research report on Wednesday, July 12th. Piper Jaffray Companies reiterated an “overweight” rating and set a $32.00 price objective (up previously from $30.00) on shares of Accelerate Diagnostics in a research report on Monday, June 5th. Zacks Investment Research upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research report on Monday, May 8th. Finally, ValuEngine downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $33.00.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.